Importantly, TP53 and KRAS mutations commonly co-occur in several solid malignancies, including lung adenocarcinoma and colorectal cancer, opening the possibility that tumors harboring this combination of mutations might also carry the same ARS oncogenic mechanisms and therapeutic susceptibilities as KRAS/TP53-mutant PDACs [81, 82]. The gene discussed is TP53; the disease is lung adenocarcinoma.